Why the study?
Does home treatment with low-molecular-weight heparin maintain safety and reduce costs compared to hospital treatment in patients with proximal deep vein thrombosis?
Population
201 patients presenting with proximal deep vein thrombosis, without known risk factors for pulmonary…
Comparison
Home treatment from the outset with… vs Hospital treatment for the first 10 days…
Design
RCT, randomized
Follow-up
up to 6 months
Authors
Loading...
Supports outpatient LMWH for proximal DVT to reduce costs without safety loss; confirms equivalence in randomized evidence.
Does home treatment with low-molecular-weight heparin maintain safety and reduce costs compared to hospital treatment in patients with proximal deep vein thrombosis?
Home treatment of proximal deep vein thrombosis with low-molecular-weight heparin is as safe and effective as hospital treatment, while significantly reducing healthcare costs.
Henri Boccalon (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: